Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials

Zhenzhen Yin
Jinqiang You
Youyou Wang
Jinlin Zhao
Shengpeng Jiang
Ximei Zhang
Peiguo Wang
Zhen Tao
Xin Wang
Zhiyong Yuan

Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

Correspondence: Xin Wang; Zhiyong Yuan
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Tel +86 22 2334 5609
Fax +86 22 2334 5607
Email samwx@163.com; zyuan@tmu.edu.cn

Purpose: To determine the efficacy and late toxicities of moderate (2.5–4 Gy) hypofractionated radiotherapy (H-RT) in localized prostate cancer, a meta-analysis of published randomized clinical trials comparing moderate H-RT with conventional fractionated RT (C-RT) was performed.

Materials and methods: Systematic search on published randomized clinical trials in English according to Cochrane review guidelines in databases of Pubmed, Embase, Cochrane, web of science, and Wiley Online Library was carried out. Outcomes of interests were biochemical and clinical disease failure (BCDF), biochemical failure (BF), overall survival (OS), and late toxicities.

Results: Seven of the 365 studies fulfilled inclusion criteria with 8,156 participants. Compared with C-RT, moderate H-RT showed a lower BF rate (risk ratio [RR] = 0.80, 95% CI: 0.68–0.95, \( P = 0.009 \)), while did not improve OS (RR = 0.68, 95% CI: 0.78–1.02, \( P = 0.10 \)). There was no significant difference in BCDF rates between H-RT and C-RT (RR = 0.92, 95% CI: 0.82–1.02, \( P = 0.12 \)). The H-RT was deeply grouped into dose-escalated H-RT (with a higher biologically effective dose [BED\(_{10}\)] than C-RT) and no dose-escalated H-RT; dose-escalated H-RT significantly decreased BCDF rate compared with C-RT (RR = 0.84, 95% CI: 0.73–0.96, \( P = 0.01 \)). Regarding late toxicities, there is no significant difference in late gastrointestinal (GI; RR = 0.97, 95% CI: 0.71–1.33, \( P = 0.85 \)) and genitourinary (GU) toxicities (RR = 1.04, 95% CI: 0.87–1.24, \( P = 0.69 \)). When subgrouped into dose-escalated H-RT (with a higher BED\(_{10}\) compared with C-RT) and no dose-escalated H-RT, dose-escalated H-RT increased GI toxicity (RR = 1.62, 95% CI: 1.26–2.09, \( P = 0.0002 \)) and GU toxicity (RR = 1.28, 95% CI: 1.05–1.55, \( P = 0.01 \)), while no dose-escalated H-RT significantly lowered GI toxicity (RR = 0.81, 95% CI: 0.70–0.94, \( P = 0.005 \)) and placed no influence on GU toxicity (RR = 1.02, 95% CI: 0.88–1.20, \( P = 0.77 \)).

Conclusion: This meta-analysis provides reliable evidence that moderate H-RT decreases BF rate, while does not improve OS. Compared with C-RT, H-RT with an increase in BED\(_{10}\) improved BCDF rates significantly, and accordingly, an increase in BED\(_{5}\) will result in elevated late GI and GU toxicities.

Keywords: prostate neoplasm, hypofractionation, radiotherapy, randomized trial

Introduction
Prostate cancer is one of the predominant malignancies in men throughout the world. External beam radiotherapy is one of the most important treatment options. Previous randomized trials have shown that dose-escalation conventional fractionated...
Hypofractionation and exploring different fraction sizes, including noninferiority trials and superiority trials, have been widely, and several large-scale Phase III randomized trials, including noninferiority trials and superiority trials, have published their results recently. However, large, Phase III trials on extreme hypofractionation, also known as Sterotactic Body Radiation Therapy, which is a more recent development, are lacking. Only retrospective trials and small sample prospective trials are available, and no standard fractionation size recommendation is made. Thus, extreme H-RT is restricted to clinical trials.

In order to investigate the current status of moderate H-RT in the treatment of prostate cancer, including efficacy and toxicity, in this meta-analysis, only Phase III randomized trials comparing moderate H-RT with C-RT in nonsurgery prostate cancer were included.

Materials and methods
Search strategy and selection criteria
This meta-analysis is reported in accordance with the Preferred Reporting Items for systematic Reviews and Meta-analyses Statement and was registered at International Prospective Register of Systematic Reviews (number CRD42016049464).

Published randomized controlled trials comparing H-RT and C-RT for localized prostate cancer were included. We searched Pubmed, Embase, Science Direct, Wiley online library, the Cochrane Library, and CENTRAL from the date of their inception until August 22, 2018, for relevant articles. We also searched abstracts from the most important international meetings: ASTRO, ESTRO, ASCO. We searched for “prostate cancer” AND “hypofractionation” AND “radiotherapy”. All relevant keyword variations were used for these three terms. We restricted our searches to reports published in English. Two independent reviewers screened the title and abstract of retrieved articles. Studies that seemed to meet the inclusion criteria were selected for full-text review. Disagreements between the two reviewers were resolved by discussion.

Study selection and data extraction
We regarded studies as eligible for inclusion if they are randomized Phase III clinical trials comparing H-RT with C-RT in patients with localized prostate cancer without surgery. Exclusion criteria were as follows: observational and retrospective studies. Two reviewers independently reviewed abstracts and full-text articles. We resolved disagreements about inclusion or exclusion by consensus or by involving a third reviewer. Standardized data abstraction forms were used by trained reviewers to extract data from each study. To assess the risk of bias of randomized clinical trials, we used predefined criteria based on the Cochrane Risk of Bias tool (ratings: low, unclear, high risk of bias). We synthesized the data on the majority of outcomes qualitatively. To retrieve data not reported in publications, we contacted authors of the respective papers.

Outcomes
The primary end point of interest was biochemical and clinical disease failure (BCDF) rate, and other main end points of interests were biochemical failure (BF) rate, overall survival (OS), and late GI and GU toxicities.

Statistical analyses
All rates assessed were carried out for statistical efficacy analysis using the risk ratio. We used the Cochran Q test to assess heterogeneity between studies. We also did F testing to assess the magnitude of the heterogeneity between studies, with values <25% as minimal, from 25% to 50% as moderate, and >50% as substantial heterogeneity. The fixed-effect model was used for meta-analysis in cases of nonsubstantial heterogeneity. If there was a significant heterogeneity, the random-effect model was used. Subgroup analysis was used if heterogeneity is moderate to severe. In this meta-analysis, P-value <0.05 was considered statistically significant.
Results

Our initial search identified 365 studies; only nine studies were Phase III randomized trials that fulfilled the inclusion criteria of seven studies (with data for 8,156 participants) were included in this analysis (Figure 1). Two studies published in early time were excluded, for the reason that these two studies were delivered with low radiation dose (64–66 Gy), which is much lower than the concurrent standard of care. Thus, only seven studies were included in this meta-analysis. It is to be noted that there were two pairs of comparisons in the CHHiP trial, which was counted twice. The characteristics of all these trials are presented in Table 1. All the studies were with follow-up time >5 years.

Efficacy

Six studies reported on BCDF rates. There was no significant difference in 5-year BCDF rates between H-RT and C-RT (relative risk [RR] = 0.92, 95% CI: 0.82–1.02, P = 0.12), with a moderate heterogeneity (χ² = 9.67; df = 6 [P = 0.14]; F = 38%) as shown in Figure 2A. Since the prostate cancer has a low α/β ratio at approximately 1.5 Gy, BED₁ was recalculated and all the trials were grouped into dose-escalated H-RT (with higher BED₁ compared with C-RT) and no dose-escalated H-RT (without increasing BED₁ compared with C-RT; Table S1).

As displayed in Figure 2B, one pair of comparisons in CHHiP trial (H-RT: 57 Gy/3.0 Gy [BED₁ = 171 Gy] vs C-RT: 74 Gy/2.0 Gy [BED₁ = 173 Gy]) and the study from Catton et al (H-RT: 60 Gy/3.0 Gy [BED₁ = 180 Gy] vs C-RT: 78 Gy/2.0 Gy [BED₁ = 182 Gy]) were categorized into no dose-escalation H-RT group (RR = 0.85, 95% CI: 0.73–0.96, P = 0.01) and dose-escalated H-RT group (RR = 0.98, 95% CI: 0.68–1.33, P = 0.63). Other studies were grouped into dose-escalated H-RT with a BED₁ > 180 Gy, equally to EOD > 76 Gy, which significantly reduced BCDF rates compared with C-RT (RR = 0.84, 95% CI: 0.73–0.96, P = 0.01), with a small heterogeneity (χ² = 4.11, df = 6 [P = 0.39]; I² = 3%).

Four studies reported on BF rates. Patients who received H-RT showed a lower BF rate compared with C-RT (RR = 0.80, 95% CI: 0.68–0.95, P = 0.009), without heterogeneity (χ² = 0.99; df = 3 [P = 0.80]; F = 0%), as shown in Figure 3A. And six studies reported on OS rates. There was no significant difference in OS (RR = 0.89, 95% CI: 0.78–1.02, P = 0.10) between H-RT and C-RT; also no heterogeneity was noted (χ² = 0.85; df = 3 [P = 0.68]; F = 0%), as shown in Figure 3B.

Toxicity

There is no significant difference in late GI (RR = 0.97, 95% CI: 0.71–1.33, P = 0.85; Figure 4A) and GU toxicities (RR = 1.04, 95% CI: 0.87–1.24, P = 0.69; Figure 5A) at 5 years. Since severe heterogeneities existed, subgroups were deeply analyzed. Several studies have supported that α/β ratio is 4–6 Gy for GI and GU late toxicities. Therefore, BED₃ was calculated for late toxicities. Studies were also divided into dose-escalated (BED₃ in H-RT higher than that in C-RT) and no dose-escalated H-RT groups (BED₃ in H-RT was lower than that in C-RT; Table S1). Dose-escalated H-RT was associated with higher late toxicity of GI (RR = 1.62, 95% CI: 1.26–2.09, P = 0.0002; Figure 4B) and GU (RR = 1.28, 95% CI: 1.05–1.55, P = 0.01) at 5 years (Figure 5B), without heterogeneities. Whereas, no dose-escalated H-RT significantly decreased GI toxicity (RR = 0.81, 95% CI: 0.72–1.33, P = 0.005, Figure 4B) and did not increase GU toxicity (RR = 1.02, 95% CI: 0.94–1.28, P = 0.77, Figure 5B).

Publication bias

Publication bias regarding outcomes was not assessed because there are fewer than 10 studies required to detect funnel plot asymmetry.
Table 1 Characteristics of randomized studies comparing H-RT with C-RT for localized prostate cancer

| Study                        | Patients | Comparison              | N  | BCDF | BF  | OS  | GI  | GU  | Primary end point | Follow-up (months) |
|------------------------------|----------|-------------------------|----|------|-----|-----|-----|-----|------------------|--------------------|
| Hoffman et al<sup>10</sup> J Clin Oncol 2018 | Low–high risk T1b-2 N0 | H-RT: 72/2.4 Gy C-RT: 75.6/1.8 Gy | 111 | 10   | –   | 19  | 11  | 15  | Toxicity         | 102                |
| Catton et al<sup>11</sup> J Clin Oncol 2017 | Intermediate risk (T1-2c N0) | H-RT: 60/3.0 Gy C-RT: 78 Gy/2.0 Gy | 1,206 | 109  | 97  | 76  | 54  | 135 | BCDF             | 72                 |
| Lee et al<sup>12</sup> J Clin Oncol 2016 | Low risk (T1-2 N0) | H-RT: 70/2.5 Gy C-RT: 73.8/1.8 Gy | 1,092 | 86   | 39  | 49  | 121 | 16 | BCDF             | 69.6               |
| Dearnaley et al<sup>13</sup> Lancet Oncol 2016 | Low–high risk (T1-T3a N0) | H-RT1: 60/3.0 Gy H-RT2: 57/3.0 Gy C-RT: 74/2.0 Gy | 3,216 | 88   | 132 | 87  | 105 | 110 | BCDF             | 62                 |
| Incrocci et al<sup>14</sup> Lancet Oncol 2016 | Intermediate–high risk (T1b-4Nx-0) | H-RT: 64.6/3.4 Gy C-RT: 78/2.0 Gy | 804 | 80   | 89  | 61  | 59  | –   | BCDF (relapse-free survival) | 60                 |
| Pollack et al<sup>15</sup> J Clin Oncol 2013 | Intermediate–high risk (T1-3 N0) | H-RT: 70.2/2.6 Gy C-RT: 76/2.0 Gy | 303 | 35   | 33  | –   | –   | 16  | 13  | BCDF             | 68.4               |
| Arcangeli et al<sup>16</sup> I Int J Radiat Oncol Biol Phys 2012 | Predominately high risk (T1-3 N0) | H-RT: 62/3.1 Gy C-RT: 80/2.0 Gy | 168 | –    | 13  | 7   | 15  | –   | FFBF            | 70                 |

Abbreviations: BCDF, biochemical and clinical disease failure; BF, biochemical failure; C-RT, conventional fractionated radiotherapy; FFBF, freedom from biochemical failure; H-RT, hypofractionated radiotherapy; GI, gastrointestinal; GU, genitourinary; OS, overall survival.

Discussion

Several previously randomized Phase III clinical trials compared traditional radiation dose (64–70 Gy) to dose-escalated RT (74–80 Gy), and all consistently demonstrated improved disease-free survival with escalated dose.1,2,5 Thus, dose escalation has become the current standard for care, although with increased acute and late GI and GU toxicities. Because of the lower α/β ratio in prostate tumor compared with surrounding normal tissue, hypofractionation, theoretically, may bring about an additional increase in biological equivalent dose, which means, compared with C-RT, higher dose per fraction may achieve better tumor killing and bring treatment benefit. Our findings in this meta-analysis supported this hypothesis; moderate H-RT significantly decreased biological failure rate, though without improving OS. Because of the low progression and long natural history of prostate cancer, it is difficult to increase OS significantly. One comparison of trial from Dearnaley et al<sup>10</sup> (57 Gy/3 Gy vs 76 Gy/2 Gy) and a study from Catton et al<sup>13</sup> (60 Gy/3 Gy vs 78 Gy/2 Gy) are no dose escalation, which showed no improvement in BCDF rates compared with C-RT. Other comparisons with dose-escalated H-RT presented a significantly decreased risk

![Image](381x108 to 535x210)

Figure 2 (Continued)
Figure 3 Forest plots for survival with hazard ratios. (A) Overall OS. (B) OS subgroup analysis. Note: *Indicates that another comparison from the trial conducted by Dearnaley et al was in order to differentiate from the first comparison.

Abbreviations: OS, overall survival; C-RT, conventional fractionated radiotherapy; H-RT, hypofractionated radiotherapy.
of BCDF (RR =0.84, 95% CI: 0.73–0.96, P=0.01, I²=3%), which means that moderate H-RT with a dose escalation helps decreasing BCDF.

Radiation-induced toxicity is an extremely important limitation and can cause great concerns when H-RT is delivered with dose escalation. It is difficult for radiotherapy oncologists to balance between efficacy and toxicity. Previous randomized trials using C-RT had demonstrated that dose escalation increased GI and GU toxicities. What matters is that whether moderate H-RT, especially those with an increase in BED, brings about increase in late toxicities. The results showed that there are no significant differences in GI (RR =0.97, 95% CI: 0.71–1.33) and GU (RR =1.04, 95% CI: 0.87–1.24) toxicities in patients available for analysis, but with severe heterogeneity. BED, were recalculated and used as a predictor for late GI and GU toxicities. For those with an increase in BED, in H-RT, the results showed a significant increase in late GI toxicity with an RR of 1.62 (95% CI: 1.26–2.09, P=0.0002) and in late GU toxicity with an RR of 1.81 (95% CI: 1.40–2.35, P<0.0001) compared to C-RT.

Figure 4 Forest plots for GI toxicity with hazard ratios. (A) Overall GI toxicity. (B) GI toxicity sub-grouped into dose escalation and no escalation groups.

Note: Indicates that another comparison from the trial conducted by Dearnaley et al was in order to differentiate from the first comparison.

**Abbreviations:** C-RT, conventional fractionated radiotherapy; H-RT, hyperfractionated radiotherapy; GI, gastrointestinal.

| Study or subgroup | H-RT Events | Total | C-RT Events | Total | Weight (%) | Risk ratio M-H, random, 95% CI | Year | Risk ratio M-H, random, 95% CI |
|-------------------|-------------|-------|-------------|-------|------------|--------------------------------|------|--------------------------------|
| Pollack et al 2013| 16          | 85    | 22          | 96    | 13.2       | 0.82 (0.46, 1.46)               | 2013 |                                |
| Hoffman et al 2014| 11          | 102   | 5           | 101   | 6.8        | 2.18 (0.78, 6.05)               | 2014 |                                |
| Dearnaley et al 2016| 105     | 882   | 111         | 893   | 20.5       | 0.87 (0.68, 1.11)               | 2016 |                                |
| Lee et al 2016    | 121         | 542   | 75          | 533   | 20.2       | 1.59 (1.22, 2.06)               | 2016 |                                |
| Dearnaley et al 2016| 95       | 841   | 111         | 852   | 20.4       | 0.82 (0.64, 1.07)               | 2016 |                                |
| Catton et al 2017 | 54          | 608   | 82          | 690   | 18.8       | 0.65 (0.47, 0.90)               | 2017 |                                |
| **Total (95% CI)**| **3,060**   | **2,948** | **100**     | **0.97 (0.71, 1.33)** | | | | |
| Total events      | 402         | 406   |             |       |            |                                |      |                                |

Heterogeneity: x²=0.11, x²=24.50, df=5 (P=0.0002); I²=80%
Test for overall effect: Z=0.18 (P=0.85)

| Study or subgroup | H-RT Events | Total | C-RT Events | Total | Weight (%) | Risk ratio M-H, random, 95% CI | Year | Risk ratio M-H, random, 95% CI |
|-------------------|-------------|-------|-------------|-------|------------|--------------------------------|------|--------------------------------|
| Pollack et al 2013| 16          | 85    | 22          | 96    | 13.0       | 0.82 (0.46, 1.46)               | 2013 |                                |
| Dearnaley et al 2016| 105     | 569   | 111         | 580   | 20.7       | 0.89 (0.70, 1.13)               | 2016 |                                |
| Dearnaley et al 2016| 95       | 549   | 111         | 560   | 20.6       | 0.83 (0.65, 1.07)               | 2016 |                                |
| Catton et al 2017 | 54          | 608   | 82          | 690   | 18.8       | 0.65 (0.47, 0.90)               | 2017 |                                |
| **Subtotal (95% CI)**| **1,811** | **1,762** | **73.1**   | **0.81 (0.70, 0.94)** | | | | |
| Total events      | 270         | 326   |             |       |            |                                |      |                                |

Heterogeneity: x²=0.00, x²=2.44, df=3 (P=0.49); I²=0%
Test for overall effect: Z=2.82 (P=0.005)

| Study or subgroup | H-RT Events | Total | C-RT Events | Total | Weight (%) | Risk ratio M-H, random, 95% CI | Year | Risk ratio M-H, random, 95% CI |
|-------------------|-------------|-------|-------------|-------|------------|--------------------------------|------|--------------------------------|
| Pollack et al 2013| 16          | 85    | 22          | 96    | 13.0       | 0.82 (0.46, 1.46)               | 2013 |                                |
| Dearnaley et al 2016| 105     | 569   | 111         | 580   | 20.7       | 0.89 (0.70, 1.13)               | 2016 |                                |
| Dearnaley et al 2016| 95       | 549   | 111         | 560   | 20.6       | 0.83 (0.65, 1.07)               | 2016 |                                |
| Catton et al 2017 | 54          | 608   | 82          | 690   | 18.8       | 0.65 (0.47, 0.90)               | 2017 |                                |
| **Subtotal (95% CI)**| **2,396** | **2,455** | **100**     | **0.98 (0.72, 1.33)** | | | | |
| Total events      | 402         | 406   |             |       |            |                                |      |                                |

Heterogeneity: x²=0.11, x²=24.22, df=5 (P=0.0002); I²=79%
Test for overall effect: Z=0.16 (P=0.69)
Test for subgroup differences: x²=21.43, df=1 (P=0.00001); I²=95.3%

Test for overall effect: Z=0.01 (P=0.0002)
Compared with C-RT, H-RT delivered a higher BED, to treatment target, significantly decreased BCDF rates, and the outcomes are favorable. Also, H-RT with a higher BED, than C-RT would undoubtedly increase the late GI and GU toxicities. As is well known, clinical trials comparing moderate H-RT with C-RT were usually designed for two purposes: one is to increase BED, to target volume without increasing BED, to normal tissue in order to improve outcomes and with a purpose of not increasing late toxicities; another is with a similar tumor dose but decreased normal tissue dose to minimize toxicity. Therefore, it is quite important to balance the treatment benefits and toxicities when designing fraction size and total dose for radiotherapy, which is also the most difficult part when designing a protocol, according to the results from Brenner and Hall. Brenner et al suggested that BEDs for moderate H-RT should not exceed approximately a BED, of 183 Gy or a BED, of 102 Gy; under this guideline, several fraction patterns may be adopted. However, different fraction patterns may result in events including both disease failure and complication; there is still no consensus about the standard fraction and total dose of moderate hypofractionation. 

Several elements of this meta-analysis may be criticized. First, two early randomized trials comparing H-RT with C-RT, conducted by Yeon et al and Lukka 2005, were excluded from this meta-analysis, because the dose used in C-RT was 64–66 Gy, which is much lower than the current standard treatment of care, resulting in much higher failure rates (40%–50%) in these two trials compared with the current standard treatment. However, different fraction patterns may result in events including both disease failure and complication; there is still no consensus about the standard fraction and total dose of moderate hypofractionation.

Figure 5 Forest plots for GU toxicity with hazard ratios. (A) Overall GU toxicity. (B) GU toxicity sub-grouped into dose escalation and no escalation groups.

Note: *Indicates that another comparison from the trial conducted by Dearnaley et al was in order to differentiate from the first comparison.

Abbreviations: C-RT, conventional fractionated radiotherapy; H-RT, hypofractionated radiotherapy; GU, genitourinary.

| Study or subgroup | H-RT Events | C-RT Events | Weight (%) | Risk ratio M-H, random, 95% CI Year |
|-------------------|-------------|-------------|------------|-----------------------------------|
| Pollack et al 2013 | 13          | 85          | 14         | 96 5.8 1.05 (0.52, 2.10) 2013 |
| Hoffman et al 2014| 15          | 102         | 15         | 101 6.3 0.99 (0.51, 1.92) 2014 |
| Dearnaley et al 2016 | 57        | 863         | 66         | 725 16.6 0.73 (0.52, 1.02) 2016 |
| Lee et al 2016    | 161         | 542         | 121        | 533 26.6 1.31 (1.07, 1.60) 2016 |
| Dearnaley et al 2016 | 88        | 882         | 66         | 725 18.8 1.10 (0.81, 1.48) 2016 |
| Cotton et al 2017 | 135         | 608         | 133        | 598 25.9 1.00 (0.81, 1.23) 2017 |
| Total (95% CI)    | 3,082       | 2,778       | 100        | 1.04 (0.87, 1.24)               |
| Total events      | 469         | 415         |            |                                   |
| Heterogeneity: χ²=0.02, df=5 (P=0.10); I²=46% |
| Test for overall effect: Z=0.40 (P=0.69) |

| Study or subgroup | H-RT Events | C-RT Events | Weight (%) | Risk ratio M-H, random, 95% CI Year |
|-------------------|-------------|-------------|------------|-----------------------------------|
| Hoffmann et al 2014 | 15         | 102         | 15         | 101 4.8 0.99 (0.51, 1.92) 2014 |
| Lee et al 2016    | 161         | 542         | 121        | 533 29.8 1.31 (1.07, 1.60) 2016 |
| Subtotal (95% CI) | 644         | 634         | 34.0       | 1.28 (1.05, 1.55)                |
| Total events      | 176         | 136         |            |                                   |
| Heterogeneity: χ²=0.00, df=1 (P=0.43); I²=0% |
| Test for overall effect: Z=2.47 (P=0.01) |

| Study or subgroup | H-RT Events | C-RT Events | Weight (%) | Risk ratio M-H, random, 95% CI Year |
|-------------------|-------------|-------------|------------|-----------------------------------|
| Pollack et al 2013 | 13          | 85          | 14         | 96 4.4 1.05 (0.52, 2.10) 2013 |
| Dearnaley et al 2016 | 57        | 549         | 66         | 534 18.3 1.29 (0.93, 1.68) 2016 |
| Dearnaley et al 2016 | 57        | 549         | 66         | 534 15.4 0.84 (0.60, 1.17) 2016 |
| Cotton et al 2017  | 135         | 608         | 133        | 598 28.0 1.00 (0.81, 1.23) 2017 |
| Subtotal (95% CI)  | 1,811       | 1,762       | 66.0       | 1.02 (0.88, 1.20)                |
| Total events      | 293         | 279         |            |                                   |
| Heterogeneity: χ²=0.00, df=3 (P=0.37); I²=5% |
| Test for overall effect: Z=0.30 (P=0.77) |

| Study or subgroup | H-RT Events | C-RT Events | Weight (%) | Risk ratio M-H, random, 95% CI Year |
|-------------------|-------------|-------------|------------|-----------------------------------|
| Pollack et al 2013 | 13          | 85          | 14         | 96 4.4 1.05 (0.52, 2.10) 2013 |
| Dearnaley et al 2016 | 57        | 549         | 66         | 534 18.3 1.29 (0.93, 1.68) 2016 |
| Dearnaley et al 2016 | 57        | 549         | 66         | 534 15.4 0.84 (0.60, 1.17) 2016 |
| Cotton et al 2017  | 135         | 608         | 133        | 598 28.0 1.00 (0.81, 1.23) 2017 |
| Subtotal (95% CI)  | 2,455       | 2,396       | 100        | 1.10 (0.94, 1.28)                |
| Total events      | 469         | 415         |            |                                   |
| Heterogeneity: χ²=0.01, df=5 (P=0.23); I²=28% |
| Test for overall effect: Z=1.22 (P=0.22) |
| Test for subgroup differences: χ²=3.03, df=1 (P=0.08); I²=67.0% |
in the control group, namely in C-RT, are various, ranging from 74 to 80 Gy. Therefore, it is difficult to ascertain which group would benefit most from hypofractionation. Third, the follow-up duration is moderate, ranging from 58 to 102 months in these trials. This length of follow-up is sufficient to predict toxicities related to therapy because most chronic toxicities develop within the first 5 years. However, such a follow-up is still immature in terms of cancer outcomes due to the long natural history of prostate cancer. Lastly, to our knowledge, a meta-analysis is already available in the literature from Cao et al. However, several special aspects in this analysis are different from the study of Cao et al, including the differentiation of dose concepts with a fixed \( \alpha/\beta \) ratio of 1.5 for prostate cancer and 5 for late toxicities, and thus a definition of dose escalation and no dose escalation. Moreover, exclusion of older studies with lower doses in the standard arm and the addition of newly published trials make the conclusion more dependable.

Although with the limitations mentioned above, this meta-analysis is a pooled analysis of seven large-scale Phase III randomized trials with reliable data. The findings suggested moderate H-RT with increase in BED\(_{1.5}\) improved the treatment outcomes, while toxicity may also be increased when delivered with a higher dose in BED\(_{5}\). In order to achieve excellent tumor control and low complication, BED\(_{1.5}\) for prostate cancer and BED\(_{5}\) for late normal tissue toxicity should both be taken into consideration when designing a protocol.

Acknowledgment
This study was supported by Tianjin Medical University.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Al-Mamgani A, van Putten WL, Heemsteden WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–988.
2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–1239.
3. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–473.
4. Proust-Lima C, Taylor JM, Sécher S, et al. Confirmation of a low \( \alpha/\beta \) ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2011;79(1):195–201.
5. Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85(1):89–94.
6. Mangoni M, Desideri I, Detti B, et al. Hypofractionation in prostate cancer: radiobiological basis and clinical appliance. Biomed Res Int. 2014;2014:781340.
7. Koontz BF, Bossi A, Cozzarini C, Wiegel T, D’Amico A. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68(4):683–691.
8. Höcht S, Aebersold DM, Albrecht C. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017;193(1):1–12.
9. Incrocio L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061–1069.
10. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060.
11. Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–2332.
12. Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol. 2014;4:301.
13. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877–882.
14. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464–474.
15. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11–18.
16. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172–1178.
17. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–3868.
18. Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014;88(5):1074–1084.
19. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11–18.
20. Arcangeli G, Saracino B, Arcangeli S, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol. 2017;35(17):1891–1897.
21. Yeh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072–1083.
22. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132–6138.
23. Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–1890.
24. Hoffman KE, Voong KR, Levy LB, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018;36(29):2943–2949.
25. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.
26. Brenner DJ, Hall EJ. Are we now able to define guidelines for moderate hypofractionation in prostate cancer radiation therapy? *Int J Radiat Oncol Biol Phys*. 2018;100(4):871–873.

27. Fonteyne V, Sarrazyn C, Swimberghe M, et al. 4 weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer: interim safety analysis of a randomized Phase 3 trial. *Int J Radiat Oncol Biol Phys*. 2018;100(4):866–870.

28. Cao L, Yang YJ, Li ZW, et al. Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis. *Oncotarget*. 2017;8(2):2647–2658.
## Supplementary material

### Table S1 The biological effective dose recalculated with $\alpha/\beta$ ratio as 1.5 Gy for prostate tumor and 5 Gy for GI and GU toxicities

| Study                  | N     | Patients       | Comparison                  | BED$_{1.5}$ | BED$_{5}$ |
|------------------------|-------|----------------|----------------------------|-------------|-----------|
| Lee et al$^1$/ Clin Oncol 2016 | 1,092 | Low risk (T1-2 N0) | H-RT: 70/2.5 Gy            | H-RT: 187 Gy | H-RT: 105 Gy |
| Dearnaley et al$^2$ / Lancet Oncol 2016 | 3,216 | Low–high risk (T1-T3a N0) | H-RT1: 60/3.0 Gy           | H-RT1: 180 Gy | H-RT1: 100 Gy |
| Incrocci et al$^3$ / Lancet Oncol 2016 | 804   | Intermediate–high risk (T1b-4Nx-0) | H-RT: 64.6/3.4 Gy          | H-RT: 211 Gy | H-RT: 109 Gy |
| Hoffman et al$^4$/ Radiat Oncal Biol Phys 2014 | 203   | Low–high risk T1b-2N0 | H-RT: 72/2.4 Gy            | H-RT: 187 Gy | H-RT: 107 Gy |
| Pollack et al$^5$/ Clin Oncol 2013 | 303   | Intermediate–high risk (T1-3 N0) | H-RT: 70/2.6 Gy            | H-RT: 192 Gy | H-RT: 106 Gy |
| Arcangeli et al$^6$/ Radiat Oncal Biol Phys 2012 | 168   | High risk (T1-3 N0) | H-RT: 62/3.1 Gy            | H-RT: 190 Gy | H-RT: 100 Gy |

Abbreviations: BED, biologically effective dose; C-RT, conventional fractionated radiotherapy; GI, gastrointestinal; GU, genitourinary; H-RT, hypofractionated radiotherapy.

### References

1. Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. *J Clin Oncol*. 2016;34(20):2325–2332.
2. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol*. 2016;17(8):1047–1060.
3. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(8):1061–1069.
4. Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. *Int J Radiat Oncol Biol Phys*. 2014;88(5):1074–1084.
5. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. *J Clin Oncol*. 2013;31(31):3860–3868.
6. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012;84(5):1172–1178.